Good Morning,
Welcome to our weekly exploration of the ever-developing world of longevity investments, where the pursuit of extending human life spans becomes a tangible venture for today’s most innovative minds and powerful entities.
This week, we delve into the captivating realm where big money meets groundbreaking science. Venture Capital giants are fervently backing initiatives in biotechnology, regenerative medicine, and AI, all aimed at prolonging life and enhancing health in our later years. From LongeVC to LifeX VC, major players are at the forefront, navigating the intricate web of financial risks and ethical considerations. We also spotlight Rejuveron Life Sciences AG, a Swiss biotech pioneer, supported by renowned investors and hedge fund tycoons, leading the charge in anti-aging research. And not least, we examine the bold move by Jeff Bezos, leveraging a portion of his immense wealth to fuel biotech startups aiming to revolutionize our approach to aging.
Dive into this week’s digest and understand the conversation shaping our collective quest for longevity.
VC Giants In Billion-Dollar Quest for Longevity Breakthroughs (Forbes)
In the dynamic realm of longevity, venture capital firms are heavily investing in extending human lifespan and enhancing health in old age. This involves pouring resources into biotechnology, regenerative medicine, and artificial intelligence. However, this venture is fraught with challenges: longevity research is expensive and time-consuming, posing financial risks and ethical dilemmas, such as the social implications of life extension.
Key players like LongeVC, LifeX VC, and Longevitytech.fund are making significant strides, each offering unique expertise and robust funding. Moreover, tech moguls and generalist VCs are increasingly investing in this sector, recognizing its potential. These collaborations are pivotal in advancing longevity research, promising to accelerate the development of breakthrough therapies. This global effort signals a future where longer, healthier lives could become a reality.
THE LONGEVITY INVESTOR REPORT
This exclusive first edition has a complete sector breakdown, and an introduction to some of the key things professional longevity investors are looking at.
We’re demystifying the sector, and providing inside access to the most promising companies.
Abu Dhabi Investment Fund Bankrolls Longevity (Bloomberg)
Swiss biotech company Rejuveron Life Sciences AG, valued at nearly $400 million, has raised $75 million in Series B funding and loans. Backed by Mubadala Investment Co., hedge fund magnates Stan Druckenmiller and Alan Howard through Catalio Capital Management, and entrepreneur Christian Angermayer, Rejuveron is at the forefront of anti-aging research.
They’re developing therapies to reverse aging effects and extend lifespans, with ongoing trials for retinitis pigmentosa and sarcopenia, conditions causing vision loss and muscle weakening in the elderly. Rejuveron plans to invest in Boost Neuroscience for brain synapse regeneration and establish a presence in Abu Dhabi’s health-care hub. Their efforts are a testament to the growing interest in longevity research, offering new hopes for tackling age-related diseases and promoting longer, healthier lives.
Jeff Bezos Allocates Portion of $124B Net Worth into Longevity (Benzinga)
Earlier in 2023, Jeff Bezos, with a net worth of $124 billion, marked a significant venture into longevity science by investing in biotech startups like Altos Labs and Rejuvenate Bio. These companies are at the forefront of pioneering efforts to combat aging. Rejuvenate Bio’s research, achieving a 7% increase in mice lifespan through gene reprogramming, is a remarkable step towards potential human applications.
This innovative approach in extending life could herald a new era in medical science. However, it’s important to acknowledge that such cutting-edge technology might initially be out of reach for many, hinting at a future where access to longevity treatments could be uneven. Despite this, the investment reflects a positive and ambitious vision towards revolutionizing how we understand and approach human aging.
As we wrap up this week’s foray into the dynamic and rapidly evolving field of longevity investments, several key insights stand out.
The intersection of substantial financial backing and pioneering science reveals a compelling narrative of progress and potential in the quest to extend human life spans. With major venture capital firms, including LongeVC and LifeX VC, along with influential figures like Jeff Bezos, channeling resources into biotechnology, regenerative medicine, and artificial intelligence, the landscape is ripe for groundbreaking advancements. Rejuveron Life Sciences AG exemplifies this trend, leading anti-aging research supported by notable investors and hedge fund tycoons.
Will these advances lead to longer, healthier lives accessible to all, or will they deepen existing divides? As we continue to explore these questions, the contributions of this week’s highlighted entities and individuals offer a glimpse into a future where aging might be approached with unprecedented scientific rigor and optimism.
Keep your finger on the pulse,
The Longr Reads Team.
“Price is what you pay. Value is what you get.”
Warren Buffet, Investor
Longr Reads’ of the Week
- The start-ups seeking a cure for old age (Financial Times)
- Interview: The US tech millionaire trying to reverse his age (BBC News)
- Inconvenient Truths About Human Longevity (Oxford Academic)
